DK0944389T3 - Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer - Google Patents

Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer

Info

Publication number
DK0944389T3
DK0944389T3 DK97934905T DK97934905T DK0944389T3 DK 0944389 T3 DK0944389 T3 DK 0944389T3 DK 97934905 T DK97934905 T DK 97934905T DK 97934905 T DK97934905 T DK 97934905T DK 0944389 T3 DK0944389 T3 DK 0944389T3
Authority
DK
Denmark
Prior art keywords
propargyl
tumors
10dam
deazaaminopterin
treatment
Prior art date
Application number
DK97934905T
Other languages
Danish (da)
English (en)
Inventor
Francis M Sirotnak
James R Piper
Joseph I Degraw
William T Colwell
Original Assignee
Sloan Kettering Inst Cancer
Stanford Res Inst Int
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21806781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0944389(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer, Stanford Res Inst Int, Southern Res Inst filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of DK0944389T3 publication Critical patent/DK0944389T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97934905T 1996-07-17 1997-07-16 Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer DK0944389T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2190896P 1996-07-17 1996-07-17
PCT/US1997/011982 WO1998002163A1 (en) 1996-07-17 1997-07-16 Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

Publications (1)

Publication Number Publication Date
DK0944389T3 true DK0944389T3 (da) 2008-11-17

Family

ID=21806781

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97934905T DK0944389T3 (da) 1996-07-17 1997-07-16 Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer

Country Status (10)

Country Link
US (1) US6028071A (de)
EP (2) EP2258702A3 (de)
JP (2) JP2001505537A (de)
AT (1) ATE407677T1 (de)
CA (1) CA2260266C (de)
DE (1) DE69738981D1 (de)
DK (1) DK0944389T3 (de)
ES (1) ES2313737T3 (de)
PT (1) PT944389E (de)
WO (1) WO1998002163A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780808B1 (fr) * 1998-07-03 2001-08-10 Thomson Csf Dispositif a emission de champ et procedes de fabrication
US20040053836A1 (en) * 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
NZ576849A (en) * 2004-05-30 2011-03-31 Sloan Kettering Inst Cancer Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin salts
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US20110190305A1 (en) * 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
JP5897558B2 (ja) * 2010-06-02 2016-03-30 アロス セラピューティクス，インコーポレイテッド １０−プロパルギル−１０−デアザアミノプテリンによりメトトレキサート抵抗性疾患を治療するための方法
WO2012061469A2 (en) 2010-11-02 2012-05-10 Sicor Inc. Crystalline forms of pralatrexate
EP2794610B1 (de) 2011-12-21 2016-03-09 Plus Chemicals SA Verfahren und zwischenprodukte zur herstellung von pralatrexat
WO2013164856A1 (en) * 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
WO2013177713A1 (en) * 2012-05-31 2013-12-05 Alphora Research Inc. Process for preparation of an antifolate agent
WO2014016740A2 (en) 2012-07-23 2014-01-30 Fresenius Kabi Oncology Ltd. Improved process for the preparation of pralatrexate
WO2014020553A1 (en) 2012-08-03 2014-02-06 Fresenius Kabi Oncology Ltd. Salts of pralatrexate
WO2014068599A2 (en) * 2012-11-02 2014-05-08 Hetero Research Foundation Process for pralatrexate
WO2014187274A1 (zh) * 2013-05-24 2014-11-27 苏州明锐医药科技有限公司 普拉曲沙及其中间体的制备方法
CN103588775B (zh) * 2013-11-12 2016-08-17 连云港恒运医药科技有限公司 普拉曲沙降解杂质及其制备方法
AU2016277929B2 (en) 2015-06-16 2020-09-10 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis

Also Published As

Publication number Publication date
DE69738981D1 (de) 2008-10-23
EP0944389B1 (de) 2008-09-10
EP0944389A4 (de) 2001-04-04
JP2001505537A (ja) 2001-04-24
EP2258702A2 (de) 2010-12-08
ATE407677T1 (de) 2008-09-15
US6028071A (en) 2000-02-22
WO1998002163A1 (en) 1998-01-22
EP0944389A1 (de) 1999-09-29
CA2260266A1 (en) 1998-01-22
JP5271677B2 (ja) 2013-08-21
EP2258702A3 (de) 2011-11-30
ES2313737T3 (es) 2009-03-01
PT944389E (pt) 2008-12-03
JP2009091361A (ja) 2009-04-30
CA2260266C (en) 2011-01-18

Similar Documents

Publication Publication Date Title
DK0944389T3 (da) Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer
IL136690A0 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
DK0728006T3 (da) Anvendelse af mannosephosphater til behandlingen af fibrotiske lidelser
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
DK0500773T3 (da) Ikke-glycosyleret FGF-4 og præparater indeholdende dette
DE60020681D1 (de) Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
EP0281070A3 (de) Pharmazeutische Zusammensetzung für die Krebsbehandlung
DK0463126T3 (da) Fremgangsmåder til fremme af sårheling og genopretning af væv
PT1076561E (pt) Terapia de combinacao para o tratamento de tumores
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
EP0588477A3 (en) Medicinal composition comprising tcf-ii
DE69927714D1 (de) 19-nor-vitamin d3 derivate mit calciumspiegel erhöhender wirkung
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
DE3485282D1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
ATE200865T1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien